Corrona, LLC

Author Of 1 Presentation

Observational Studies Poster Presentation

P0845 - Characteristics of patients initiating ocrelizumab vs other disease-modifying therapies in a US national multiple sclerosis registry (ID 1224)

Presentation Number
Presentation Topic
Observational Studies



Ocrelizumab (OCR) was approved in 2017 in the United States (US) for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). Real-world data describing the characteristics of patients initiating OCR are limited. The Corrona MS Registry is a US prospective observational registry that, as of August 2019, encompasses 11 private and academic sites and 781 patients aged ≥18 years, including 631 patients receiving a disease-modifying treatment (DMT) at the time of enrollment.


To describe the characteristics of patients enrolled in the Corrona MS Registry who initiated OCR vs other MS DMTs.


This analysis included patients who initiated a DMT ≤24 months before or at registry enrollment (which began in August 2017) to ensure comparable treatment availability across groups, considering the 2017 approval of OCR. Enrollment visit characteristics were calculated separately for patients initiating OCR, oral/injectable DMTs or other intravenous (IV) DMTs. Patient Global Impression of Change (PGIC) score was reported for patients who started DMT before enrollment.


The analysis population included 326 patients (52% of treated registry patients); 71% initiated OCR (n=233), 16% initiated oral (n=43) or injectable (n=9) DMTs and 13% initiated another IV DMT (n=41). Most patients (n=299) initiated a DMT before enrollment. Compared with patients initiating OCR, those initiating oral/injectable or other IV DMTs were more likely to have a relapsing-remitting disease course (80% vs 89% and 88%, respectively), were younger (mean [SD] age, 51 [11] vs 48 [11] and 44 [12] years, respectively) and had a shorter mean disease duration (13 vs 10 and 8 years, respectively). Fewer patients in the OCR group initiated treatment as a first- or second-line therapy (36%) than in the oral/injectable (67%) or other IV groups (59%). Mild disability (scores ≤1) on the Patient Determined Disease Steps was reported by 49% of patients in the OCR group and 65% and 54% in the oral/injectable and other IV DMT groups, respectively. Improvement on the PGIC was reported by 50%, 27% and 63% in the OCR, oral/injectable and other IV groups, respectively.


In these unadjusted analyses of Corrona registry data, patients initiating ocrelizumab in the 2 years after launch were older and had higher disability levels at the time of enrollment than those initiating other DMTs. Real-world outcomes will continue to be examined as the registry matures.